Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
PARP1 is the target of clinically approved anti-cancer drugs whose in vivo efficacy has been hard to predict. Here the authors show how an altered active site formed between PARP1 and Histone PARylation Factor 1 (HPF1) changes the efficacy of some of these inhibitors.
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/33d6d10fa6924050954dfbd2aa320cee |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|